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ENGLISH SUMMARY 
Iron is essential for living organisms, and tight regulation of iron homeostasis is vital 
since defective iron homeostasis can have harmful effects. Throughout life, the brain 
takes up iron from the periphery through the blood-brain barrier (BBB) and the blood-
cerebrospinal fluid (CSF) barrier. The turnover of iron is extremely low, which can 
explain why iron concentrations increase in the brain in healthy aging. In pathology, 
like hemorrhagic stroke and many neurodegenerative diseases, defective iron 
homeostasis can result in iron accumulation and consequently changes in the cellular 
distribution of iron and cell damage. Furthermore, an inflammatory reaction in the 
brain parenchyma is a common response in these diseases. The inflammatory process 
involves the activation of microglia and astrocytes and infiltration of circulating 
immune cells, which further perturbs iron homeostasis. Glia cells upregulate their iron 
uptake and increase numerous iron-related proteins, which include heme oxygenase-
1 (HO-1) that releases free iron by degrading heme, and the iron storage protein, 
ferritin.   
Several iron-related proteins, such as lipocalin 2 (LCN2) and Zrt-, Irt-like protein 14 
(ZIP14) are regulated by inflammatory stimuli in the periphery. LCN2 functions to 
limit available iron for bacteria and participates in iron homeostasis, while ZIP14 
imports divalent metal ions in the liver, heart, and pancreas. However, there is still 
lacking evidence of whether they are regulated during pathology in the brain. This 
dissertation focuses on iron handling in the brain in conditions with iron overload and 
neuroinflammation. In order to study this, animal models of hemorrhagic stroke, i.e. 
intracerebral hemorrhage (ICH) and intraventricular hemorrhage (IVH), and a model 
of chronic neurodegeneration were used.  
In Study I, the role of the choroid plexus in handling hemoglobin was studied using 
in vitro and in vivo models of IVH. The regulation of the transferrin receptor, ferritin, 
HO-1, LCN2 and lipocalin receptor, 24p3R was investigated after hemoglobin 
exposure. An experimental model of ICH was established by administrating arterial 
autologous whole blood into the striatum of rats. Characterization of the model 
includes investigation of iron content, ferritin, and HO-1 expression. Study II 
examined the modulation of ZIP14 expression in the model of ICH, whereas Study III 
investigated the regulation of ZIP14 in an experimental model of chronic 
neurodegeneration in the substantia nigra pars reticulata (SNpr). Since astrocytes were 
shown to modulate ZIP14 expression in both models, it was examined whether ZIP14 
is regulated by blood derivatives, iron overload, and inflammation in cultures of 
astrocytes.  
Results from Study I demonstrate that the choroid plexus upregulates HO-1, acute-
phase protein LCN2, and ferritin in response to hemoglobin exposure. While ferritin 
is probably upregulated as a cellular defense mechanism to store iron in a non-toxic 
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form thereby limiting iron-induced cell damage, upregulation of LCN2 may be 
detrimental to the choroid plexus. Study II and III show that reactive astrocytes 
increase their expression of the iron importer, ZIP14, in animal models with increased 
brain iron and neuroinflammation. Furthermore, astrocyte cultures increase their 
Zip14 gene expression in response to hemoglobin, iron overload, and inflammation. 
Due to the dysregulation of iron homeostasis observed in ZIP14 knockdown 
astrocytes, we suggest that ZIP14 plays an essential role in astrocytic iron homeostasis 
in pathology. Additionally, ZIP14 could serve as a neuroprotective mechanism by 
limiting free extracellular iron and neuronal cell death.  
Together, these studies show that LCN2 and ZIP14 may play significant roles in 
handling iron in the choroid plexus and astrocytes, respectively, in pathological 
conditions. 
VII 
DANSK RESUME 
Jern har essentielle funktioner for overlevelse af organismer, og regulering af jern-
homøostasen er vigtig, da overskydende jern kan være toksisk. Hjernen optager jern 
fra cirkulationen gennem blod-hjerne barrieren (BBB) og blod-cerebrospinalvæske 
barrieren (blood-CSF-barrier) gennem hele livet. Da hjernen har en lille omsætning 
af jern, ses der er en øget jernkoncentration i hjernen ved aldring. Denne 
jernkoncentration er endnu højere ved patologiske tilstande såsom cerebrale 
hæmoragier og neurodegenerative sygdomme og kan føre til jernakkumulering, 
ændringer i den cellulære distribuering af jern og cytotoksisitet, der kan være med til 
at forværre sygdomme. Derudover er sygdommene ofte akkompagneret af 
intraparenkymal inflammation, hvilket fører til aktivering af mikroglia og astrocytter 
samt invasion af immunceller fra cirkulationen, som er med til yderligere at forstyrre 
jernhomøostasen. Blandt andet er det tilfældet, at gliaceller opregulerer deres 
jernoptag og øger ekspressionen af forskellige jern-relaterede proteiner, såsom heme 
oxygenase 1 (HO-1), der frigiver ved nedbrydelse af hæm, samt 
jernlagringsproteinet, ferritin.  
Mange jernrelaterede proteiner, herunder lipocalin 2 (LCN2) og Zrt-, Irt-like protein 
14 (ZIP14) reguleres af inflammatoriske stimuli i periferien. LCN2 spiller en rolle i 
forsvaret mod bakterielle infektioner, hvor det mindsker tilgængeligheden af frit jern, 
mens ZIP14 fungerer som en importer af divalente metalioner i leveren, hjertet og 
bygspytkirtlen. Der er dog stadig ingen evidens for, hvordan disse proteiner reguleres 
under patologiske tilstande i hjernen. Denne afhandling fokuserer på 
jernhåndteringen i hjernen i tilstande med jernophobning og neuroinflammation. For 
at undersøge dette er der anvendt forskellige dyremodeller, herunder modeller for 
intracerebral hæmoragi (ICH) og intraventrikulær hæmoragi (IVH), samt en model 
for kronisk neurodegeneration.  
I Studie I undersøges håndteringen af hæmoglobin i plexus choroideus in vitro og in 
vivo i en model for IVH. Regulereingen af transferrin receptor, ferritin, HO-1, LCN2 
og lipocalin receptor, 24p3R blev undersøgt efter hæmoglobinbehandling. Derudover 
blev en model for ICH etableret ved at injicere arterielt, autologt blod i striatum på 
rotter. Modellen blev karakteriseret for dens jernindhold samt ferritin og HO-1 
ekspression og blev senere brugt i Studie II. I Studie II og III blev ZIP14-
ekspressionen undersøgt i modellen for intracerebral hæmoragi samt i en 
eksperimentel model for kronisk neurodegeneration i substantia nigra pars reticulata 
(SNpr). Ekspression og regulering af ZIP14 blev endvidere undersøgt i astrocytter, 
da begge in vivo modeller viste ZIP14-opregulering i astrocytter. Astrocytkulturer 
blev behandlet med blod, jern og pro-inflammatoriske cytokiner, hvorefter ZIP14-
ekspressionen blev undersøgt.  
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Resultater fra Studie I demonstrerer, at plexus choroideus opregulerer HO-1, LCN2 
og ferritin i forbindelse med hæmoglobinbehandling. Mens ferritin formentlig 
opreguleres som en cellulær forsvarsmekanisme, der lagrer jern og dermed mindsker 
risikoen for jerninduceret cellulær skade, formodes det, at opreguleringen af LCN2 
kan forårsage skade på plexus choroideus.   
Resultater fra Studie II og III viser, at reaktive astrocytter øger deres ekspression af 
jerntransporteren, ZIP14. Den øgede ekspression af ZIP14 i astrocytter ses i begge 
dyremodeller, der blandt andet er kendt for at have inflammation samt jernophobning. 
Desuden viser studier med astrocytter, at ZIP14 reguleres efter behandling med 
hæmoglobin, øget jern og inflammation in vitro. Desuden viser vi, at mindsket 
ZIP14-ekspression er associeret med en ubalance i den astrocytiske jernhomøostase, 
hvilket kan tyde på, at ZIP14 spiller en vigtig rolle for jernhomøostasen i astrocytter. 
Disse resultater indikerer, at opregulering af ZIP14 virker som en forsvarsmekanisme 
ved at mindske neuronal celledød ved sygdom med inflammation og jernakku-
mulering.  
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CHAPTER 1. INTRODUCTION  
Iron is fundamental for living organisms, as it is involved in numerous cellular 
processes such as DNA synthesis, oxygen transport, and the electron transport chain 
in the mitochondria. Although iron is necessary for cellular processes, unbound (free) 
iron promotes the production of reactive oxygen species through Fenton chemistry 
and can potentially cause oxidative stress, which in turn can lead to cellular damage 
and death (1). In the attempt to balance tissue iron concentrations and homeostasis, 
maintaining constant iron concentrations via regulation of import and export from the 
body is of importance. Iron homeostasis is primarily regulated at the site of uptake, 
and thus if iron accumulates in various organs, it hardly leaves (2).  
Maintaining proper iron concentrations in the brain is also essential, since 
inappropriately high concentrations of iron, as in other organs, are toxic to the brain 
parenchyma. In the brain, iron is crucial for the synthesis of neurotransmitters and 
myelin production and thus plays a vital role in brain development and maintenance 
of normal brain functions. Developmental iron deficiency is thus thought to impair 
brain development by hampering mitotic activity, transmitter synthesis, and myelin 
production, while brain iron overload may propagate oxidative damage causing 
neuronal cell death (3–5).  
Throughout life, the brain acquires iron from the circulation via transport of 
transferrin-bound iron through the blood-brain barrier (BBB) and blood-cerebrospinal 
fluid barrier (blood-CSF barrier). This uptake is developmentally regulated, being 
particularly high early in life (6,7). The turnover of iron in the brain is very low, and 
as the uptake of iron into the brain occurs throughout life, an increased iron 
concentration is seen in the brain even in healthy aging (4). The concentration of iron 
differs among brain regions with the highest concentrations in, e.g. the basal ganglia 
and substantia nigra (8).  
The following paragraphs cover systemic iron uptake and regulation, major routes of 
cellular iron uptake and storage mechanisms, iron transport through the brain barriers, 
and iron handling in neurons and glial cells. Moreover, iron handling is elucidated in 
hemorrhagic stroke, neurodegeneration, the inflammatory choroid plexus, and 
reactive glial cells. 
1.1. SYSTEMIC IRON UPTAKE AND REGULATION 
Iron is absorbed as heme or non-heme iron primarily by the enterocytes present in the 
proximal duodenum. Although non-heme iron constitutes most of the iron in diets, its 
absorption is less efficient compared to heme-iron, which, on the other hand, typically 
constitutes only a small part of dietary iron (9). The gastrointestinal uptake of non-
heme iron is mediated by divalent metal transporter 1 (DMT1) expressed on the apical 
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membrane of enterocytes. DMT1, which belongs to the natural resistance-associated 
macrophage protein (NRAMP) family, is well-functioning at the low pH in the 
duodenum (10–12). Here it transports non-heme ferrous iron (Fe2+) into the 
enterocytes. Upon its luminal uptake, ferric iron (Fe3+) is reduced to Fe2+ through the 
ferrireductase duodenal cytochrome b (Dcytb) localized on the apical membrane of 
enterocytes (13,14).  
Despite being an integral source of iron, little is known about the uptake of heme iron. 
It is suggested that it enters the enterocytes via heme carrier protein 1, although its 
function as a heme transporter is still debated (2). Subsequent degradation of heme by 
heme oxygenase 1 (HO-1) releases Fe2+ that enters the cytosolic pool of iron together 
with iron absorbed through DMT1 (2,15). Fe2+ is then either oxidized and 
incorporated in ferritin, the major iron storage protein capable of storing 
approximately 4500 Fe3+ atoms or exported into the circulation through the cellular 
iron-exporter ferroportin that transports Fe2+ (13,16). The export of Fe2+ through 
ferroportin is influenced by the membrane-bound ferroxidases, hephaestin and 
ceruloplasmin that oxidize Fe2+ to Fe3+ (2,17,18). In the circulation, Fe3+ rapidly binds 
to apo-transferrin, which has a high affinity for iron. Transferrin is mainly synthesized 
in the liver and can bind up to two Fe3+, generally referred to as holo-transferrin (19). 
In pathological conditions with iron overload, the carrying capacity of transferrin can 
be exceeded leading to the presence of non-transferrin-bound iron (NTBI) in the blood 
plasma. NTBI is observed in the human disorder hemochromatosis, where iron is 
deposited throughout the body (20,21). An exception is the brain that shows only a 
modest increase in iron deposition in a mouse model of hemochromatosis. The modest 
increase was suggested to relate to the protective mechanisms of the BBB and blood-
CSF barrier (22).  
Systemic iron homeostasis is regulated by recycling of iron from dying red blood cells, 
mobilization of hepatic iron stores, and the gastrointestinal iron absorption, whereas 
excretion does not contribute to regulation of iron homeostasis (2). The 
gastrointestinal iron absorption is regulated by the liver-derived hormone, hepcidin, 
which is secreted in response to inflammation and systemic iron overload (23,24). It 
regulates the iron absorption by direct interaction with ferroportin at the basolateral 
side of enterocytes causing its proteolysis, thereby abolishing its capacity to export 
iron (25). Thus in conditions with increased hepcidin, the expression of ferroportin 
lowers, which results in decreased iron transport into the circulation (23).  
1.2. CELLULAR IRON UPTAKE AND STORAGE 
Transferrin carries iron from the site of absorption via the circulation to cells 
expressing transferrin receptors that subsequently facilitate receptor-mediated 
endocytosis of the holo-transferrin (6). Another mechanism for iron uptake relies on 
the uptake of NTBI although, in normal physiological conditions, NTBI is absent in 
the circulation. This means that NTBI-mediated uptake of iron is likely to occur only 
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in pathological conditions, where the iron-binding capacity of transferrin is exceeded 
(21).  
1.2.1. TRANSFERRIN-MEDIATED IRON UPTAKE 
The majority of cells in the body obtain iron via transferrin receptor-mediated 
endocytosis in clathrin-coated vesicles. The transferrin receptor is a transmembrane 
receptor that consists of two subunits, each capable of binding one holo-transferrin. 
Binding of holo-transferrin to the transferrin receptor triggers the formation of an 
endosome with a lower pH (Fig. 1.1) (26). Fe3+ dissociates from transferrin in the 
acidic environment of the endosome and is subsequently reduced to Fe2+ by a 
ferrireductase, like six-transmembrane epithelial antigen of the prostate 2 (STEAP2), 
STEAP3, or Dcytb (27,28). Fe2+ is then transported across the endosomal membrane 
via DMT1 and transferrin is recycled to the plasma membrane (6,12,29,30). 
1.2.2. NON-TRANSFERRIN-BOUND IRON UPTAKE 
For uptake of NTBI, Fe3+ is reduced to Fe2+ by a ferrireductase and then imported via 
an NTBI transporter (Fig. 1.1). Although cells are generally capable of acquiring 
NTBI (21,31), the uptake mechanisms are less described. It is widely accepted that 
NTBI uptake involves transport by DMT1, which is the most important transporter 
for intestinal iron uptake (32). Nevertheless, accumulative data suggest the 
involvement of other newly identified transporters in NTBI uptake. These transporters 
include the transient receptor potential channel (TRPC), L-type and T-type calcium 
channels, Zrt-, Irt-like protein 8 (ZIP8), and ZIP14 (21,33–36). The following section 
will focus on DMT1 and ZIP14 for uptake of NTBI. 
DMT1 is a well-characterized iron transporter. It has multiple transmembrane 
domains and is located both in cellular membranes and endosomes, thus emphasizing 
the dual role of DMT1 in iron uptake (37,38). DMT1 transports divalent metal ions 
and is thought to transport Fe2+ predominantly (10). Four isoforms exist, of which two 
contain an iron-responsive element (IRE) in its 3’ untranslated region (UTR) (30,39). 
The isotypes exhibit differential regulation and distribution patterns, for instance, the 
isoforms containing an IRE are located in the cell membrane and regulated by iron 
status, whereas the others are located in the endosomal compartment and not regulated 
by iron status (30,40).  
In addition to DMT1, ZIP14 is also able to transport divalent metal ions. ZIP14 is an 
integral membrane protein and a member of the Zrt- and Irt-like protein family (41). 
It is detected in various non-neuronal tissues and cell types, such as liver, pancreas, 
heart, white adipose tissue, and hepatocytes (42–45). In nervous tissue, there is 
evidence for ZIP14 expression in the brain in vivo and cultured neurons and astrocytes 
(35,46,47). ZIP14 was initially characterized as a zinc transporter (48) but has later 
gained status as being an iron transporter (36,49).  
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Figure 1.1. Two routes for cellular iron uptake. Left: Transferrin-bound iron uptake: The 
transferrin receptor (TfR) mediates uptake of holo-transferrin. Ferric iron (Fe3+) is detached 
from transferrin in the endosome, reduced to ferrous iron (Fe2+) by a ferrireductase and then 
pumped into the cytosol by divalent metal transporter 1 (DMT1) where iron can be stored in 
ferritin, while transferrin is recycled to the cell surface. Right: Non-transferrin-bound iron 
(NTBI) uptake: NTBI transporters, such as DMT1 or Zrt-, Irt-like protein 14 (ZIP14), facilitate 
uptake of Fe2+. Upon uptake, Fe3+ is reduced to Fe2+ by a ferrireductase and Fe2+ is then 
transported into the cytosol through, e.g. DMT1 or ZIP14, where iron incorporates in ferritin.  
1.2.3. STORAGE OF IRON 
Once the uptake of iron has occurred, it can either be used in cellular processes, 
incorporated in ferritin, or exported through ferroportin to preserve iron homeostasis. 
Ferritin is important for binding and storage of iron. It consists of two isoforms, a 
heavy chain (H) and a light chain (L) with a molecular weight of 19 kDa and 21 kDa, 
respectively. The H chain exerts ferroxidase activity, while the L chain functions in 
mineralization and iron nucleation (50,51). Of note, lack of ferritin H is lethal in the 
early stages of development, whereas mutations in ferritin L can result in iron 
accumulation (52,53). Together, ferritin H and L form a spherical structure that stores 
iron in a non-toxic form, thereby neutralizing its deleterious effects. 
1.2.4. REGULATION OF CELLULAR IRON HOMEOSTASIS 
Regulation of iron homeostasis occurs at both the systemic and cellular level. Control 
of cellular iron homeostasis is complex and involves regulation of proteins implicated 
in iron uptake, storage, and export. It is partly controlled by post-transcriptional 
regulation via the IRE/iron-regulatory proteins (IRP) system. IREs are located in 
either the 3’-UTR of mRNA encoding iron uptake genes, DMT1 and transferrin 
receptor, or the 5’-UTR of mRNA encoding genes involved with iron storage or 
export, ferritin and ferroportin (54). IRPs that bind with IREs located at 3’-UTR 
increase mRNA stability, while binding to IREs in the 5’-UTR block their translation. 
During iron overload, IRPs lose their affinity to IREs, thus destabilizing DMT1 and 
CHAPTER 1. INTRODUCTION 
21 
transferrin receptor, while the translation of ferritin and ferroportin increases 
(13,54,55). 
1.3. IRON IN THE BRAIN 
The brain is separated from the circulation by physical barriers, i.e. the blood-brain 
barrier (BBB) denoted by brain capillary endothelial cells and the blood-cerebrospinal 
fluid barrier (blood-CSF barrier) consisting of choroid plexus epithelial cells. The 
capillaries ensheathed by the choroid plexus epithelial cells are fenestrated, which 
contrasts with brain capillary endothelial cells and choroid plexus epithelial cells that 
are connected to adjacent cells by tight junctions, thereby forming the BBB and blood-
CSF barrier. The barriers regulate the brain microenvironment by governing the entry 
of potentially toxic compounds, pathogens, and nutrients into the brain (56,57). 
Selective transporters exist to regulate the transport of vital components across the 
barriers, e.g. the transferrin receptor, which is responsible for iron uptake. Both 
barriers are major sites of iron exchange between the brain and periphery. The 
transferrin receptor is highly expressed on the luminal side of the BBB and has a broad 
distribution on the choroid plexus epithelial cells, where it facilitates iron transport 
from the circulation into the brain and CSF (6,58–60).  
1.3.1. IRON TRANSPORT ACROSS THE BRAIN BARRIERS 
It is generally acknowledged that the transferrin receptor constitutes the most central 
mechanism for iron uptake at the BBB. How iron is transported through the BBB is 
still a matter of debate, and different hypotheses exist. One route of iron transport into 
the brain is the transferrin receptor-mediated transcytosis, where endosomes 
containing holo-transferrin in complex with transferrin receptor traverse the 
endothelial cells of the BBB and release holo-transferrin into the brain interstitium 
(Fig. 1.2A) (61,62). Another route of transport involves transferrin receptor-mediated 
endocytosis. This is followed by separation of iron from the transferrin-transferrin 
receptor complex in the acidic environment of the endosome. Iron is then reduced by 
a ferrireductase, pumped through the endosome via DMT1 and reaches the abluminal 
surface of the endothelial cells, whereas the apo-transferrin and transferrin receptor 
are recycled to the luminal surface (Fig. 1.2A). At the abluminal surface, iron is 
exported into the brain interstitium via ferroportin and subsequently oxidized by 
hephaestin or ceruloplasmin (27,30,63). The latter observation combined with the fact 
that transferrin receptors were never detected at the abluminal side of the endothelium 
are observations that point against the idea of transport of transferrin across the BBB.  
Much similar to the transport through the BBB, different pathways are described for 
iron uptake at the blood-CSF barrier (Fig. 1.2B). The choroid plexus epithelium 
expresses the transferrin receptor and is shown to transport iron via transcytosis of 
holo-transferrin (64). Additionally, several studies have proved evidence for 
expression of DMT1, ferrireductase, ferroportin, and ferroxidases in the choroid 
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plexus (57,65,66), indicative of transferrin receptor-mediated endocytosis and 
subsequent export by ferroportin. The choroid plexus epithelial cells have abundant 
expression of ferritin (57,67), suggesting they are also able to accumulate and store 
iron. Iron that is not stored in the choroid plexus is exported into the CSF (64). Due 
to the absence of a diffusional barrier between the CSF and the brain interstitium, 
components of the CSF may diffuse into the interstitium (57).  
Once iron, transported through the BBB and blood-CSF barrier, enters the brain 
interstitium or CSF, it binds to apo-transferrin and enters transferrin-receptor 
expressing cells. Opposite to the plasma transferrin, transferrin within the CSF is 
believed to be saturated in non-pathological conditions, indicating that iron may bind 
to low molecular weight complexes like citrate, ascorbate, or ATP from where it can 
be taken up by neurons and glial cells by less characterized mechanisms (68–70).  
1.3.2. IRON UPTAKE IN NEURONS AND GLIAL CELLS  
Neurons 
Neurons express transferrin receptors, suggesting that they are instrumental for 
neuronal iron uptake. Neuronal transferrin receptors are markedly upregulated during 
iron deficiency, which clearly advocates that neuronal iron uptake is regulated by the 
IRE/IRP system (6). Neurons in most regions of the brain contain iron. However, iron 
levels are higher later in life (71).  
It is proposed that NTBI continuously occurs in the brain interstitium, where it might 
serve as the primary source of iron for glial cells, that in contrast to neurons, are devoid 
of detectable transferrin receptor (60,70,72). There is currently no solid evidence for 
NTBI uptake in neurons in vivo, but ZIP8 and ZIP14 are proposed to mediate uptake 
of iron in neuronal cultures. The expression of ferrireductase STEAP2 in the cellular 
membrane seemingly support this notion (35). 
Microglia 
Broadly distributed throughout the brain, microglia continuously survey the 
microenvironment and react to pathological changes in the brain. In non-pathological 
conditions, microglia exhibit an inactivated or ramified state, characterized by their 
thin, motile processes. In this state, they play pivotal roles in support of neurons, e.g. 
by releasing neurotrophic factors (73). Microglia take up NTBI in vitro and enhance 
their accumulation of iron in the absence of transferrin (31,74). More recently, 
primary microglia were reported to express Dmt1 and the microglial cell line, IMG 
cells, exhibit Dmt1, Zip8, and Zip14 gene expression (75).  
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Figure 1.2. Iron transport across the blood-brain barrier (A) and blood-cerebrospinal fluid 
(CSF) barrier (B). A-B. Transcytosis: Holo-transferrin complexes with the transferrin receptor 
(TfR) on the BBB and blood-CSF barrier. The complex is internalized, and holo-transferrin is 
released in the brain or CSF, and the transferrin receptor is recycled. Endocytosis: Binding of 
holo-transferrin to the transferrin receptor triggers a cascade that results in internalization of 
the complex. Inside the endosome, iron is separated from transferrin, reduced by a 
ferrireductase and transported into the cytosol through divalent metal transporter 1 (DMT1). 
Iron is then either stored in ferritin or exported through ferroportin. Exported iron is oxidized 
by a ferroxidase thus enabling binding of iron to transferrin. 
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Astrocytes 
Astrocytes, the most abundant glial cell type in the brain, perform multiple functional 
and supportive roles for the brain microenvironment. Hence, astrocytes provide 
support for the BBB and neighboring neurons and maintain the extracellular ion 
homeostasis in the brain. In contrast to neurons and other glial cells, astrocytes of the 
normal brain are surprisingly vague in their expression of molecules related to iron 
homeostasis. For instance, they lack transferrin receptors in vivo (60). Therefore, their 
uptake of iron probably relies on NTBI uptake rather than transferrin receptor-
mediated iron uptake. However, in vitro astrocytes were demonstrated to contain 
transferrin receptors and ferritin in cell cultures (76,77). NTBI uptake in cultured 
astrocytes has been studied comprehensively (33,76–80). In vitro, astrocytes can take 
up ferric iron from low molecular weight sources like ferric ammonium citrate 
(31,80). Dcytb or stromal cell-derived receptor 2 present in their cellular membranes 
are proposed to reduce Fe3+ after which it is imported via NTBI transporters (77,80). 
DMT1 probably mediates some NTBI uptake, but an expression of other transporters 
such as ZIP14 and TRPC were also recently reported in astrocytes in vitro (33,78).  
1.4. IRON IN THE PATHOLOGICAL BRAIN 
The pathological brain is supposedly challenged by inflammation and deposition of 
iron. There is a well-recognized link between inflammation and iron accumulation. 
Thus, chronic systemic inflammation causes iron retention in the reticuloendothelial 
system to limit the amount of available iron thereby preventing the growth and 
survival of bacterial microorganisms (81).  
Neuroinflammation is a multifaceted response to many CNS injuries, such as 
hemorrhagic stroke and neurodegeneration, and includes barrier dysfunction, 
infiltration of immune cells from the periphery, and activation of glial cells that 
together release inflammatory mediators, such as IL-1β and IL-6 (82–84). 
Furthermore, iron deposition occurs in the pathological brain and may be caused by 
iron-rich microglia and invading monocytes/macrophages that phagocytize damaged 
cells and subsequently undergo apoptosis, releasing iron into the brain (83). This iron 
deposition is supposedly even more exaggerated in cerebral hemorrhage, in which 
substantial amounts of iron are released from dying blood cells (85,86).  
1.4.1. HEMORRHAGIC STROKE 
Intracerebral hemorrhage (ICH) is a subtype of hemorrhagic stroke and accounts for 
approximately 10-15% of all strokes. In nearly 50% of patients with ICH, the bleeding 
spreads into the ventricular space (intraventricular hemorrhage, IVH), which is 
correlated to a worsened outcome (87). In ICH, rupture of a cerebral blood vessel 
releases erythrocytes into the brain parenchyma, thereby causing primary and 
secondary injury. The primary injury denotes the damage that occurs within minutes 
after the ictus because of the mass effect created by the hematoma, while secondary 
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injury refers to the long-term damage caused by the presence of blood in the brain and 
the hematoma resolution. Blood in the brain parenchyma and hematoma resolution 
are accompanied by inflammation, cytotoxicity of the blood, and oxidative stress 
(88,89). 
Rupture of a vessel and subsequent bleeding into the brain parenchyma is associated 
with activation of microglia and astrocytes and infiltration of neutrophils and 
macrophages that secrete chemokines and cytokines, e.g. interleukin-1 (IL-1), IL-6, 
and tumor necrosis factor-α (TNF-α) (90–93). Together, the release of inflammatory 
mediators and formation of reactive oxygen species causes neuronal cell death (Fig. 
1.3), modulates the basement membrane and increases the permeability of the BBB, 
resulting in brain edema (92,94,95). Evidence suggests that neutrophils participate in 
brain injury by activating microglia and astrocytes, amplifying inflammation, and 
compromising the integrity of the BBB. Thus, depletion of neutrophils is reported to 
attenuate these mechanisms, at least until 14 days after ICH (96).  
While cytotoxicity of blood in the brain is attributable to many components, this 
section will focus on the toxicity of hemoglobin and iron, two main components of 
erythrocytes. Erythrocytes gradually start to lyse and release their content, i.e. 
hemoglobin, into the brain interstitium (Fig. 1.3) (85,97). The free hemoglobin 
complexes with haptoglobin, which has a high affinity for the CD163 receptor, located 
at the cell membrane of macrophages and microglia. CD163 is regulated by an 
increased extracellular content of hemoglobin-haptoglobin complexes as early as 24 
hours after ICH (98–100) and is thought to play a distinct time-dependent role after 
ICH. For instance, CD163-/- is correlated with smaller lesions and decreased iron 
content in early phases of ICH, while CD163-/- results in larger lesions and increased 
iron in the long term, suggesting that CD163 mediates brain injury in the early phase 
of ICH and beneficial effects in the long term (101).  
Hemoglobin degrades intracellularly into heme that is further degraded into free iron 
by HO-1. HO-1 is expressed by microglia, astrocytes, and neurons and is upregulated 
in the early phase after ICH (85). Increased HO-1 expression in astrocytes is suggested 
to be independent on the uptake of hemoglobin and heme, as astrocytes are proposed 
to take up small amounts hemoglobin (102). Comparable to CD163, HO-1 displays a 
distinct temporal role following ICH that has harmful effects in the early phase, while 
promoting recovery in later stages (103). The pathological increase in HO-1 
expression may cause iron accumulation, which in microglia and macrophages 
coincide with increased ferritin levels (85).  
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Figure 1.3. Cellular responses to intracerebral hemorrhage. Microglia and astrocytes activate, 
and inflammatory immune cells invade the brain parenchyma through, e.g. the blood-brain 
barrier (BBB) after rupture of a cerebral vessel. Microglia and macrophages phagocytose 
erythrocytes and contribute to the production of inflammatory mediators, such as interleukin-
1β (IL-1β), IL-6, and reactive oxygen species (ROS), along with activated astrocytes. As 
erythrocytes lyse, hemoglobin (Hb) and iron are released into the brain. Hb is scavenged by 
haptoglobin (Hp) and taken up via CD163 expressed on macrophages and microglia. The 
increased iron uptake in microglia and macrophages results in an increased ferritin expression. 
Collectively, inflammation and iron dysregulation exert neuronal injury after ICH. NTBI, non-
transferrin-bound iron.  
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Experimental Models of Intracerebral Hemorrhage 
Many models have been established to study ICH, of which the most extensively used 
are intracerebral injection of either autologous whole blood or collagenase (104). The 
blood model has existed since the 1960s, where whole blood was injected into the 
brain of larger animals (105–107). Rats and mice models were later developed. In the 
rat model, arterial blood is sampled from the femoral artery into a syringe, and 100 µl 
blood is stereotactically injected into the rat brain over 10 minutes by use of a 
microinfusion pump (108–110). This method only introduces blood and allows for 
control of hematoma size, although variations may occur as a consequence of bleeding 
into the ventricular space and backflow of injected blood along the needle injection 
site. Compared to the collagenase-induced model, studies have found milder 
neurological symptoms, less hematoma expansion, and shorter recovery (111). 
However, this method has been a useful tool in investigations of pathological changes 
that occur after ICH (85,112).  
In the collagenase-induced model, developed by Rosenberg and colleagues (113), 
0.01-0.5 U bacterial collagenase diluted in 2 µl sterile saline is administered to the 
brain, causing dissolution of the endothelial basement membrane. Ultimately, this 
results in vascular disruption and hematoma formation that starts as early as 10 min 
after collagenase administration and continues for hours (90,113–116). Rosenberg et 
al. found a concentration-dependent increase in edema formation after collagenase 
injection and that rats injected with more than 0.5 U collagenase died within 24 hours 
(113). In contrast to the whole-blood induced model, injection of bacterial collagenase 
has been shown to induce greater BBB injury, more severe tissue destruction, 
persistent neurological deficits, and a greater inflammatory response, although the 
latter is not proved (116–120).  
1.4.2. NEURODEGENERATION 
Neurodegeneration is a progressive, irreversible process with damage of neuronal 
structures and loss of their essential functions, ultimately leading to cell death. 
Neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease, and 
Parkinson’s disease are heterogeneous in their clinical pathology, some affecting 
motor skills while others cause amnesia and cognitive deficits. Common to these 
irreversible diseases, chronic inflammation and progressive iron deposition occur in 
brain areas preferentially affected by the diseases (83,121–125). Accordingly, iron 
deposits in Lewy bodies in the substantia nigra in Parkinson’s disease and in amyloid 
plaques and neurofibrillary tangles in Alzheimer’s disease (126,127). The increased 
iron concentration found in the substantia nigra of patients with Parkinson’s disease 
may be explained by increased DMT1 expression in dopaminergic neurons and 
reactive microglia in the substantia nigra pars compacta (SNpc) (128). Supporting 
this, mutations in DMT1 in animal models of Parkinson’s disease (6-
hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)) mitigates dopaminergic cell loss (128). In Alzheimer’s disease, iron is also 
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thought to contribute to the formation of amyloid plaques through the modulation of 
amyloid precursor protein processing (4). The iron deposition may result in the 
generation of reactive oxygen species, which can exacerbate the neurodegeneration. 
However, the question arises whether iron is the initial cause of neurodegeneration or 
is due to deposition from dying neuronal cells and migrating inflammatory cells from 
the circulation.  
Experimental Models of Chronic Neurodegeneration 
Neurodegeneration can be induced by intracerebral microinjections of toxins, e.g. 
ibotenic acid, MPTP, and 6-OHDA (129–131). Intrastriatal administration of ibotenic 
acid results in cytotoxicity of gamma-aminobutyric acid (GABA)ergic neurons in the 
striatum (129). Cell death among GABAergic striatal neurons projecting inhibitory 
stimuli to neurons in substantia nigra pars reticulata (SNpr) will eventually lead to 
excitotoxicity in SNpr. This excitotoxicity, exerted by glutamate, develops upon 
overstimulation of nigral neurons from the subthalamic nucleus and results in 
progressive loss of nigral neurons and shrinkage of SNpr (130,132). Shrinkage of 
SNpr is accompanied by iron deposition, long lasting gliosis, and infiltration of 
inflammatory cells from the periphery (129,132). The mechanisms by which iron 
increases in this model is not known however, it was recently proposed to be 
associated with infiltration of monocytes through a compromised BBB and an 
inflammatory response (83). 
1.5. ALTERED IRON HOMEOSTASIS IN INFLAMMATION 
Although, neuroinflammation is considered to play essential roles in tissue repair 
mechanisms within the CNS, persistent neuroinflammation can be detrimental 
(82,133). Additionally, many pathological conditions with inflammation are 
associated with altered iron metabolism (83,134).  
1.5.1. IRON HANDLING IN THE INFLAMED CHOROID PLEXUS 
The choroid plexus is in contact with many external factors and acts as an immune 
sensor. It undergoes morphological and physiological changes during aging and 
disease (87,135,136). For example, as a response to lipopolysaccharide (LPS)-induced 
inflammation, the choroid plexus induce the production of IL-1β, IL-6, and TNF-α, 
which can regulate iron-related proteins (134,137). LPS is a major component of 
Gram-negative bacteria and is often used as a model of inflammation, where it 
activates immune cells through Toll-like receptor 4 (TLR4). Expression of TLR4 in 
the choroid plexus allows them to recognize LPS (134). Accordingly, LPS-induced 
inflammation results in a robust upregulation of lipocalin 2 (LCN2) in the choroid 
plexus (138).  
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Figure 1.4. Neuroinflammation and iron overload contribute to neuronal cell death. Upon 
injury, microglia proliferate and activate, which leads to the release of pro-inflammatory 
mediators, such as interleukin-1β (IL-1 β), IL-6 and reactive oxygen species (ROS). The release 
of pro-inflammatory mediators causes astrocyte activation, an inflammatory response in the 
blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (blood-CSF barrier), and 
monocyte/macrophage invasion into the brain parenchyma through the brain barriers. As a 
response to injury, the blood-CSF barrier modulates the expression of iron-related proteins 
and produce lipocalin 2 (LCN2). Excess iron is taken up by microglia and astrocytes that both 
increase their expression of non-transferrin-bound iron (NTBI) transporters and their iron 
uptake. In microglia, this results in increased ferritin expression.   
LCN2 is an acute-phase protein that acts in the antimicrobial defense, as it chelates 
the bacterial iron-containing siderophores, thereby limiting iron availability for the 
bacteria (139). Additionally, a growing body of literature indicates that LCN2 
participates in iron homeostasis. Thus, LCN2 interacts with cell membrane receptor 
24p3R to increase or decrease intracellular iron levels (140). Based on the evidence 
that LCN2-/- mice have less BBB disruption compared to wild type mice in 
hemorrhagic stroke, LCN2 also influences barrier properties (141).  
Barrier dysfunctions are suggested to cause an imbalance in the iron exchange 
between the circulation and the brain (134). Supporting this notion, the choroid plexus 
responds rapidly to inflammation by increasing gene expression of ferritin H and 
Hamp (the gene encoding hepcidin) (136). The authors propose that these changes in 
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the choroid plexus can lead to changes in the composition of the CSF, which may 
affect cells within the brain, like microglia and astrocytes (136).  
1.5.2. IRON HANDLING IN REACTIVE MICROGLIA 
Microglia are the earliest responders to CNS injury and increase in number in the early 
phase of inflammation (92). During activation, microglia change into amoeboid shape 
with hypertrophied processes (132). Their activation can be elicited by a myriad of 
stimuli, such as infection, trauma, pro-inflammatory cytokines, and neuronal injury 
(142). For instance, microglia express TLR4 (143) that enable them to detect LPS. 
Interestingly, LPS induces a pro-inflammatory response that activates microglia and 
accentuates their cellular iron uptake and DMT1 expression (Fig. 1.4) (75,144,145). 
Furthermore, hepcidin increases in inflammatory conditions and is shown to decrease 
the expression of ferroportin while increasing DMT1 expression in microglia (145), 
supporting that microglia increase their iron content during inflammation. In addition 
to changes in iron homeostasis, microglia secrete a variety of cytokines, IL-1α, IL-1β, 
IL-6, TNF-α, chemokines, and reactive oxygen species that engage the activation of 
astrocytes (146–150).  
1.5.3. IRON HANDLING IN REACTIVE ASTROCYTES  
Increasing evidence suggests that astrocytes, upon activation, lose their 
neuroprotective role while gaining neurotoxic functions that exacerbate 
neuroinflammation (150,151). It is suggested that they undergo major morphological 
and molecular changes during activation. Regarding morphological changes, the 
conversion to a reactive state induces hypertrophy of astrocyte processes (152). In 
contrast to microglia, astrocytes do not proliferate in inflammation-induced CNS 
insults. However, an increase in the number of astrocytes is seen in traumas, where 
they contribute to scar formation (150,153,154).  
Similar to microglia, astrocytes modify their iron homeostasis during inflammation. 
For instance, they induce DMT1 expression and ferritin expression in vitro when 
stimulated with pro-inflammatory cytokines or LPS (33,145,155). While it is well 
documented that astrocytes take up more iron during inflammation and iron overload 
(Fig. 1.4) (31,33), their iron uptake mechanisms are still debated. DMT1 has received 
much attention and support in its function as a significant NTBI transporter during 
inflammation (33). However, DMT1 expression in vivo is restricted to astrocyte 
endfeet (65). Based on this, others claim that DMT1 only contributes to iron uptake 
in non-pathological conditions, while new NTBI transporters are important during 
pathology (80). ZIP14 is regulated by iron overload and inflammation, suggesting it 
plays a role in pathological conditions (43,44,156,157). 
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Together, this implies an essential role for the choroid plexus and activated glial cells 
in modifying the inflammatory response and iron homeostasis, which may be relevant 
in neurological conditions where basal levels of iron and pro-inflammatory mediators 
are elevated (4,82). 
 
33 
CHAPTER 2. THESIS OBJECTIVES 
The objective of this dissertation was to understand how the brain handles iron in 
conditions with inflammation and iron overload, using in vitro cultures and in vivo 
models of intraventricular hemorrhage, intracerebral hemorrhage and neurodegene-
ration. 
The hypotheses were: 
- The choroid plexus responds to hemoglobin exposure by changing the 
expression of iron-handling proteins (Study I) 
- The expression of the iron-transporter ZIP14 increases in conditions with 
inflammation and iron overload, caused by cerebral hemorrhage (Study II) 
- The expression of ZIP14 increases in an experimental model of chronic 
neurodegeneration with inflammation and iron accumulation as a mechanism 
to limit deposition of available free iron (Study III) 
In order to address the overall objective, three separate studies were conducted. The 
aims of the studies were: 
Study I: To investigate the regulation of iron-related proteins, i.e. HO-1, ferritin, and 
LCN2, in the choroid plexus in vitro and in vivo following exposure of hemoglobin.  
Study II: To establish an experimental model of ICH that would enable analysis of 
iron deposition and correlative increases in HO-1 and ferritin expression. The model 
was additionally employed to examine the regulation of ZIP14 during ICH in vivo and 
astrocyte cultures in experimental conditions mimicking the molecular events 
occurring during ICH.   
Study III: To investigate the expression and regulation of ZIP14 in an experimental 
model of chronic neurodegeneration with inflammation and progressive iron 
deposition. Results were supplemented with in vitro studies of ZIP14 expression and 
regulation in astrocytes. 
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CHAPTER 3. METHODS AND RESULTS 
3.1. STUDY I 
Regulation of iron-related proteins in the choroid plexus by hemoglobin 
Lisa J Routhe, Jianming Xiang, Hong Ye, Ya Hua, Torben Moos, Guohua Xi, and 
Richard F Keep 
Manuscript submitted 
Abstract  
Introduction: Following intraventricular hemorrhage (IVH), lysis of red blood cells 
within the ventricular system can release hemoglobin and heme into CSF. Heme may 
be further degraded by heme oxygenase (HO) hence increasing the concentration of 
iron in CSF. The response of the choroid plexus (CP), site of the blood-CSF barrier, 
within the ventricles to IVH has not been well studied. It may be a site of injury or 
iron clearance. 
Aims: In this study, we aimed to characterize the hemoglobin-induced regulation of 
iron-handling proteins in the choroid plexus in vitro and in vivo. 
Methods: In vitro, freshly isolated CP, primary cultures of CP epithelial cells, and 
immortalized rat choroid plexus epithelial Z310 cells were treated with different 
concentrations of hemoglobin, after which RT-qPCR was performed to evaluate 
regulation of ferritin, HO-1, transferrin receptor (TfR), lipocalin (LCN2), and 
lipocalin receptor (24p3R). In vivo, mice had an intraventricular injection of 
hemoglobin or saline and CP ferritin, HO-1, and LCN2 expression was examined by 
immunohistochemistry.  
Results: While there were some differences in the baseline of mRNA levels between 
the different in vitro preparations (notably in the Z310 cells), each of the preparations 
showed similar increases in the mRNA levels for ferritin, HO-1, and LCN2, but not 
TfR and 24p3R after 6 hours of hemoglobin exposure. In vivo, immunohistochemistry 
confirmed hemoglobin-induced upregulation of ferritin, HO-1, and LCN2.  
Discussion: The impact of IVH on the CP has received little attention. The current 
study shows increased ferritin expression, which may protect the CP from 
hemoglobin-derived iron. The impact of the increased HO-1 expression is less certain, 
as it both degrades potentially toxic heme and releases iron that can enhance free 
radical production. Similarly, while LCN2 may be involved in clearing iron from CSF, 
it may also participate in CP iron overload, neuroinflammation and ICH-induced brain 
injury.  
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3.2. STUDY II 
To mimic ICH in Study II, the experimental model with injection of autologous blood 
into the brain parenchyma was established. The impact of the intraparenchymal 
deposition and degradation of blood on iron deposition and changes in protein 
expression was examined by Perls’ staining for histological iron, and 
immunohistochemistry for detection of HO-1 and ferritin in rats sacrificed 1, 3, 7, 14, 
and 28 days post-surgery. Subsequently, the role of ZIP14 was investigated.  
3.2.1. PERLS’ STAINING 
Perls’ staining is a method used to visualize non-heme iron present when iron is bound 
to ferritin or transferrin. The staining reaction depends on the conversion of 
ferrocyanide into crystal precipitates, Prussian blue, in an acidic environment and 
detects both ferrous and ferric iron with main sensitivity for detection of ferric iron 
(158). The acidic environment initiates iron release from ferritin and transferrin and 
thus enables the formation of precipitates with deep blue color (158). This method is 
extensively used to detect iron in tissue sections either as Perls’ staining alone or in 
combination with DAB-enhancement that increases the sensitivity of the staining 
reaction (159).  
In the ICH model, pathological iron deposition was not detected in the area of 
hemorrhage in rats sacrificed 1 day post-surgery (Fig. 3.1). However, iron-positive 
cells became apparent in the perihematomal zone 3 days after ICH. The staining was 
observed in cells with a morphology corresponding to amoeboid macrophages or 
neutrophils. After 7 days, a blue rim was observed between the hematoma and the 
adjacent tissue. Here iron-positive cells showed round, as seen after 3 days, or 
ramified morphology (microglia or macrophages). The blue rim was still apparent 
after 14 and 28 days (Fig. 3.1) and stainings were similar to that observed after 7 days, 
thus suggesting that iron is present in inflammatory cells after ICH in rats.  
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Figure 3.1. Perls' stain after induction of ICH. Non-heme iron was detected in the tissue after 
3 days and onwards. Based on the morphology of the cells, iron staining was observed in 
amoeboid (arrow) and ramified (arrowhead) immune cells. Scale bar = 100 µm and 20 µm. 
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3.2.2. IMMUNOCYTOCHEMISTRY 
Resolution of the hematoma in ICH includes degradation of the red blood cells with 
release of intracellular proteins into the extracellular space, intracellular conversion 
of hemoglobin to heme and iron-mediated by HO-1, and storage of unbound iron by 
ferritin (85). Immunohistochemical analysis showed a rapid upregulation of HO-1 in 
the ipsilateral side as early as 1 day after ICH, while the contralateral side remained 
unlabeled (Fig. 3.2). This expression was still pronounced after 28 days, which 
indicate a prolonged HO-1 expression after ICH. A vast majority of HO-1 was 
observed in cells with a morphology corresponding to microglial cells (1, 3, 7, 14, and 
28 days), although some astrocyte-like and weakly stained neuronal-like cells were 
also observed.   
Cells exhibiting ferritin immunoreactivity revealed a temporal upregulation from 1 
day to 28 days after ICH (Fig. 3.3). Based on cell morphology, ferritin staining was 
induced in macrophage and microglia-like cells adjacent to the site of the hematoma. 
In contrast, the contralateral side showed few ferritin-labeled cells. These results were 
in agreement with results published by other investigators, which used the same model 
of ICH (85). In further studies, we used rats sacrificed after 1, 7, 14, and 28 days.  
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Figure 3.2. HO-1 in the experimental model of intracerebral hemorrhage (ICH). 
Representative images of HO-1 in the contralateral (Contra) and ipsilateral side (Ipsi) of rats 
euthanized 1, 3, 7, 14 and 28 days after ICH. HO-1-positive cells were found in the ipsilateral 
side with most cells observed during the early phase of ICH (1 and 3 days). A majority of HO-
1 immunoreactive cells had a morphology corresponding to microglia/macrophages after ICH. 
However, astrocyte-like cells were also observed. In contrast, the contralateral side remained 
unlabeled. Scale bars = 100 µm and 20 µm. 
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Figure 3.3. Ferritin in the experimental model of intracerebral hemorrhage (ICH). 
Representative images of ferritin in the contralateral (Contra) and ipsilateral side (Ipsi) of rats 
euthanized 1, 3, 7, 14 and 28 days after ICH. In the early phase of ICH, a few ferritin-positive 
cells were observed (1-7 days). In contrast, more ferritin-positive cells appeared in the 
perihematomal zone after 14 and 28 days. Ferritin expression is confined to cells with 
microglia/macrophage morphology. Scale bars = 100 µm and 20 µm. 
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Upregulated astrocytic ZIP14 expression in an experimental model of 
intracerebral hemorrhage 
Lisa J Routhe, Maj S Thomsen, Guohua Xi, and Torben Moos 
Manuscript in preparation 
Abstract 
Introduction: Intracerebral hemorrhage (ICH) is associated with an increased level 
of non-transferrin-bound iron (NTBI) causing an overall increase in the concentration 
of iron in the brain. NTBI may represent a toxic form of iron that promotes oxidative 
stress through the Fenton reaction chemistry. The transporter Zrt-, Irt-like protein 14 
(ZIP14) is suggested to import NTBI through the cellular membrane. Although all 
cells in the brain probably take up NTBI, regulated uptake of NTBI in astrocytes may 
be neuroprotective. In the present study, the occurrence of ZIP14 was characterized 
after hemorrhagic stroke in vivo and in vitro.  
Methods: Male Sprague-Dawley rats were stereotactically injected with autologous 
whole blood (ICH) and sacrificed after 1, 7, 14, and 28 days. ZIP14 expression was 
analyzed with immunohistochemistry, Western blotting, and RT-qPCR. Primary rat 
astrocyte cultures were treated with whole blood or hemoglobin and analyzed for 
protein and mRNA expression of ZIP14 after 1 or 7 days.  
Results: After ICH, upregulation of ZIP14 was observed together with an increase in 
the number of ZIP14-positive cells in the ipsilateral side 7, 14, and 28 days after ICH 
compared to the contralateral side. There was no difference in the gene expression of 
either Zip14 or Il-6 between the ipsilateral and contralateral side or between the 
ipsilateral sides of ICH and sham-operated animals. ZIP14 co-localized with GFAP 
in the experimental model of ICH, suggestive of an astrocytic expression. This was 
further supported in vitro, where gene expression analysis revealed increased Zip14 
expression in astrocytes treated with hemoglobin or 5% whole blood.  
Conclusion: The increased expression of ZIP14 is indicative of the brain’s attempt to 
recover following ICH via uptake of iron by astrocytes.  
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3.3. STUDY III 
Altered expression of ZIP14 (SLC39A14) is part of the astrocytic reaction to 
chronic neurodegeneration with iron overload 
Lisa J Routhe, Ida K Andersen, Lissa V Hauerslev, Issa I Issa, Torben Moos, and 
Maj S Thomsen 
Manuscript submitted 
Abstract 
Introduction: Neurodegeneration is associated with inflammation and a mismanaged 
iron homeostasis, leading to increased concentration of non-transferrin-bound iron 
(NTBI) in the brain. NTBI can be taken up by cells expressing Zrt-, Irt-like protein-
14 (ZIP14), which is regulated by iron overload and inflammatory cytokines like 
interleukin-1β (IL-1β) and IL-6. Thus, this study focuses on the involvement and 
regulation of Zip14 in chronic neurodegeneration with iron overload and 
inflammation. 
Methods: Male Wistar rats were unilaterally injected with the glutamate receptor 
agonist, ibotenic acid, in the striatum, which eventually leads to excitotoxicity and 
neuronal loss in substantia nigra pars reticulata (SNpr). ZIP14 expression was 
measured in the SNpr using immunohistochemistry, Western blotting, and RT-qPCR. 
Furthermore, primary astrocyte cultures were examined for Zip14 mRNA expression 
after stimulation with ferric ammonium citrate (FAC), IL-6, or IL-1β. Iron uptake was 
investigated after treatment with IL-1β and siRNA-mediated ZIP14 knockdown. 
Results: ZIP14 was widely expressed in the normal rat brain. In the lesioned SNpr, 
reactive astrocytes revealed altered ZIP14 expression with a main confinement to cell 
bodies and cellular processes. In vitro, FAC and IL-1β stimulation resulted in 
increased Zip14 expression and increased uptake of 59Fe. Similarly, increased 59Fe 
uptake was observed after siRNA-mediated ZIP14 knockdown. 
Conclusion: In conclusion, these data imply a vital role of ZIP14 for astrocytic iron 
homeostasis, and provides evidence for astrocytes as being important for management 
of iron in the pathological brain. 
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CHAPTER 4. GENERAL DISCUSSION 
Brain iron increases with age, but the observations that iron accumulation is even 
higher in neurodegeneration has led to the speculations that dysregulated iron 
homeostasis may contribute to the brain pathology (4,160,161). While there has been 
a development in the understanding of systemic iron homeostasis, mechanisms of iron 
handling in the brain are still poorly understood. Thus, studies of iron handling in the 
brain often draw parallels to known mechanisms in the periphery. The aim of this 
dissertation was to study iron handling in the pathological brain. The current study 
was inspired by findings from models with systemic iron overload, e.g. 
hemochromatosis, in which NTBI increase systemically, thus triggering the induction 
of iron-handling proteins (21).  
This chapter is dedicated to a general discussion that focuses on the expression of 
iron-related proteins in the choroid plexus, with particular emphasis on LCN2, and 
the importance of astrocytic ZIP14, which are both proteins that are regulated by iron 
accumulation and inflammation (43,44,138,141,156). Lastly, model limitations are 
discussed.  
4.1. THE CHOROID PLEXUS AS A RESPONDER TO 
HEMOGLOBIN 
In contrast to many other organs, the brain shows a surprisingly small increase in iron 
accumulation during iron overload pathology, which, as mentioned, may be due to the 
protective effects of the BBB and blood-CSF barrier (22). There has been considerable 
interest in examining the BBB in stroke and only a few studies investigating the role 
of the choroid plexus epithelial cells (87). The choroid plexus is responsible for 
secretion and regulation of CSF components and suggested to play a key role in brain 
iron homeostasis (57). Existing work has confirmed a modulation of the expression 
of iron-handling proteins in the choroid plexus in response to inflammation (134). The 
modifications of the choroid plexus transport function may cause altered brain iron 
homeostasis (57,136). As there is little evidence for uptake of NTBI at the brain 
barriers (22), we decided not to look at NTBI transporters in Study I but investigated 
the regulation of many other iron-handling proteins after hemoglobin exposure. We 
found that the choroid plexus responded by increasing gene expression of Lcn2, HO-
1, Ftl, and Fth.  
The function of LCN2 has gained much attention in the last decades since it is 
upregulated in the CNS in models of Alzheimer’s, Parkinson’s disease, and 
hemorrhagic stroke (131,136,141,162). A growing body of evidence reports that 
LCN2 is regulated by blood derivatives, pro-inflammatory cytokines, and LPS 
(138,141,163–166). Supporting this notion, we found that LCN2 is upregulated in the 
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choroid plexus after hemoglobin exposure (Study I). The involvement of LCN2 in 
pathological processes in the CNS is controversial and point towards both harmful 
and protective mechanisms (167). For instance, LCN2-/- accentuates inflammation in 
an animal model of multiple sclerosis (168) although, in many other disease models, 
LCN2-/- alleviates CNS inflammation and iron accumulation (141,166,169), 
suggesting that effects of LCN2 depend on the disease. Regarding iron homeostasis, 
LCN2-/- mice had unchanged homeostasis in multiple sclerosis, whereas decreased 
ferritin expression and decreased number of ferritin-positive cells were observed in 
LCN2-/- mice after ICH (141,168). Based on these observations, it was postulated that 
LCN2 mediates iron-induced toxicity after ICH, and possibly contribute to iron 
overload in cells expressing the lipocalin receptor, 24p3R (136,141), which was found 
to be expressed in the choroid plexus in Study I.  
In Study I, hemoglobin exposure induced HO-1 expression in the choroid plexus, thus 
potentially releasing free iron. A prominent expression of ferritin found in the 
epithelial cells of the choroid plexus suggests that they play a role in iron storage 
(57,67). Following hemoglobin exposure, the increased ferritin expression, suggests 
that the choroid plexus has increased iron accumulation (Study I). Ferritin H, in 
particular, seems crucial for normal function of the choroid plexus and deletion of 
ferritin H in the choroid plexus of the lateral ventricles caused hydrocephalus in mice 
(170). Ferritin probably plays a vital role in detoxifying iron. However, whether iron 
accumulation in the choroid plexus serves to protect the brain from iron overload or 
contributes to dysfunction of the choroid plexus and the blood-CSF barrier after IVH, 
remains a central question. In a model of aceruloplasminemia with knockout of the 
ferroxidase, ceruloplasmin, the choroid plexus is the first brain region to show severe 
iron deposition (171). The authors propose that this iron accumulation may cause 
leakiness of the blood-CSF barrier as the choroid plexus is vulnerable to increased 
iron (171). Similarly, dysregulated iron homeostasis and upregulation of markers of 
oxidative stress are suggested to contribute to the morphological and functional 
changes of the choroid plexus in Alzheimer’s disease (135,136,172).  
In general, it can be speculated that changes to the brain barriers lead to a 
dysfunctional iron exchange between the circulation and brain that in turn result in 
brain iron overload, which then must be handled by neurons and glial cells in the brain 
parenchyma. This will be the topic of the following paragraph.  
4.2. UNCOVERING THE ROLE OF ASTROCYTIC ZIP14 
ALTERATIONS 
In the brain, microglia and macrophages are shown to handle iron after experimental 
ICH (Fig. 3.1 and 3.3) and experimental chronic neurodegeneration (132). However, 
we show that astrocytes also participates in the handling of iron during disease in 
Study II and III.  
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To date, reactive astrocytes have been observed in numerous animal models with CNS 
injury (150,152). Reactive astrocytes are essential in the repair of the BBB, regulation 
of leukocyte trafficking, and limiting neuronal injury. Accordingly, inhibiting reactive 
astrocytes in a transgenic mouse model with the eradication of dividing GFAP 
positive cells after stab injury resulted in prolonged BBB dysfunction and increased 
infiltration of leukocytes (173). While reactive astrocytes that limit neuronal injury 
and BBB dysfunction are beneficial, other reactive astrocytes are proposed to exert 
neurotoxic and inflammatory effects. In neurodegeneration, the presence of reactive 
astrocytes is confirmed in brain regions affected by Alzheimer’s disease, Huntington’s 
disease, and Parkinson’s disease (150,154). Findings from this dissertation are 
consistent with previous findings in that reactive astrocytes are found in rat models of 
ICH and chronic neurodegeneration (Study II and III). 
As earlier mentioned, characteristic features of hemorrhagic stroke and 
neurodegenerative diseases are excess iron accumulation and inflammation, both 
critical regulators of ZIP14 (43,44,83). Accordingly, iron status regulates ZIP14 and 
an increase in protein levels are observed in iron-loaded hepatoma HepG2 cells, 
whereas the levels decrease in iron-depleted cells (174). In line with these findings, 
Study II showed that astrocytes increase their expression of ZIP14 7-28 days after 
ICH and after stimulation with whole blood and hemoglobin in astrocyte cultures. In 
vivo, the ZIP14 upregulation coincided with iron deposition. The induction of HO-1 
in the early phase of ICH initializes release and accumulation of free iron from 3-28 
days after surgery assessed by Perls’ staining. Measuring iron with 
spectrophotometry, Wu et al. found similarly that non-heme iron concentrations were 
increased during this time course (85). Ferritin that incorporates free iron was also 
upregulated during this period, possibly as a neuroprotective mechanism (85). Since 
upregulation of ZIP14 occurs in the recovery phase of ICH, it is likely that it plays a 
role in handling excess iron occurring after the breakdown of heme. 
Besides iron overload, chronic inflammation and pro-inflammatory cytokines such as 
IL-1β and IL-6, augment hepatic ZIP14 expression (44,156). Treating astrocytes with 
LPS, as a model of inflammation, resulted in increased Zip14 expression in astrocytes 
in Study II. Whether astrocytes express TLR4 and thus respond to LPS stimulation is 
still a matter of debate. One group was not able to detect an astrocytic reaction to LPS 
and argue that the lack of response is attributable to the absence of TLR4 in astrocytes 
(150). The astrocyte cultures used in Study II may have few microglia that could 
theoretically interact with LPS and create a response. However, astrocytic TLR4 
expression was confirmed by other groups (175–177) and LPS induced Zip14 
expression (Study II), pro-inflammation, and iron homeostatic changes in astrocytes 
(178), indicating that astrocytes can interact with LPS. 
In Study III, stimulating astrocyte cultures with IL-1β and iron-induced Zip14 mRNA 
expression and revealed an increased iron uptake in activated astrocytes. 
Inflammation has been implicated in early stages of neurodegeneration, which led to 
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the investigation of regulation and involvement of ZIP14 in an excitotoxicity-induced 
model of neurodegeneration that is associated with accumulation of iron in SNpr and 
presence of inflammatory cells (129,132). Here, we found ZIP14 expression in 
hypertrophied astrocytic processes in the SNpr of the lesioned side, whereas the non-
lesioned side showed ZIP14 expression around the nuclei.  
Returning to the question, “does astrocytic ZIP14 expression reflect a protective 
response or contribute to disease mechanisms after CNS trauma?” Although there is 
no difference in the iron accumulation between ZIP14-/- mice and wild type mice, 
Dmt1 mRNA increases in ZIP14-/- mice, and ZIP14 knockout is associated with 
neuroinflammation and neurodegeneration (46,179,180). In ZIP14-/- mice, systemic 
inflammation is augmented, and IL-6 production increased compared to wild type 
mice, suggesting that ZIP14 may mediate protective effects by reducing chronic 
systemic inflammation (179). Knockdown of ZIP14 in astrocytes (in Study III) 
induced iron accumulation, proposing that ZIP14 plays an essential role in 
maintaining iron homeostasis. Thus during pathology, increases in astrocytic ZIP14 
may protect neurons from iron overload.  
4.3. MODEL LIMITATIONS 
Throughout history, animal models have contributed immensely in obtaining 
knowledge about human biology and pathology. Rats and mice are extensively used 
as models of human neurological disorders. However, it should be kept in mind that 
translation of results obtained from rodent animal models is still far from perfect and 
the models cover only aspects of human disease. For instance, in clinical ICH, 
bleeding results from an arterial source whereas experimental models with an 
injection of collagenase results in more diffuse bleeding that may originate from small 
vessels near the injection site (116–119). Using the blood model neither mimics 
clinical ICH due to the lack of vasculature pathology and disruption, which is thought 
to be the primary etiology of human ICH (89,117). Choosing the right animal model 
thus largely depends on the objectives of the experimental study. Accordingly, the 
blood model is useful when investigating mechanistic effects linked with the presence 
of blood in the brain (181), i.e., iron handling and inflammation, which was assessed 
in Study II. 
Similarly, toxin-induced neurodegeneration causes immediate onset of symptoms that 
do not resemble the insidious, progressive nature of human neurodegeneration. In the 
model of chronic neurodegeneration, the injection of ibotenic acid causes cell death 
of striatal neurons (129). The finding that N-methyl-D-aspartic acid (NMDA) 
antagonists protect against neuronal cell death in striatum suggests that ibotenic acid 
acts via the NMDA-receptor (182). The relevance of using the excitotoxicity-induced 
model of neurodegeneration is based on the role of excitotoxicity in the pathogenesis 
of neurodegeneration, where a continuous stimulation of NMDA-receptors can lead 
to neuronal injury by elevated intracellular calcium content and increased enzyme 
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activity (183). In Huntington’s disease, neurons with a high expression of NMDA-
receptors in the striatum are lost early in disease (184).  
A possible limitation of this study is the choice to use young animals when assessing 
iron handing in brain iron overload. However, this choice was made to mimic disease 
models of ICH and neurodegeneration in published papers (112,132,141). Since age 
is the predominant cause of neurodegeneration and ICH often affects the elderly, more 
attention should be given to the use of aged animals. Comparing young and aged rats, 
ICH is shown to cause decreased lesion resolution, and a delayed and more 
pronounced microglia activation in aged rats (185). Similarly, the inflammatory 
response is delayed and increased in aged rats (91,186). Despite these changes in aged 
rats, Wasserman et al. did not detect any difference in neuronal cell death compared 
to young rats (185). In contrast to microglia, more dispute prevails in the existing 
work on reactive astrocytes in young and aged rats after ICH. While one study reports 
an increased number of astrocytes in the edge of the lesion in aged rats, another study 
attributes the more severe tissue damage observed in aged rats to repression of 
astrocyte activation (185,186), thus again emphasizing the importance of the choice 
of animal model.  
Indeed, care should be taken when deciding on a suitable animal model and age of the 
animal in experiments that seek to unravel mechanisms and treatment of human 
disease.  
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CHAPTER 5. CONCLUSIONS AND 
FUTURE PERSPECTIVES 
Although a dysregulated iron homeostasis is implicated in many CNS diseases, 
relatively little is known about the underlying mechanisms. However, results obtained 
from the studies described in this dissertation have provided novel insights into the 
handling of iron during brain pathology. They demonstrate that iron accumulation and 
inflammation, two characteristic features of CNS disease, cause regulation of iron-
handling proteins, namely LCN2 and ZIP14. Furthermore, it is demonstrated that the 
choroid plexus and astrocytes participate in the iron handling during ICH and 
neurodegeneration.  
In response to hemoglobin exposure, the choroid plexus alters the expression of 
ferritin, LCN2, and HO-1. While increased ferritin expression in the choroid plexus 
may play a protective role by storing iron in a non-toxic form, upregulation of HO-1 
and LCN2 can lead to iron accumulation. Altered iron metabolism in the choroid 
plexus can interrupt the blood-CSF barrier, which, in turn, may enhance neuronal cell 
death. Thus from a clinical point of view, uncovering the influence of LCN2 in the 
CNS could add significantly to pharmacologically targeting iron overload and 
inflammation.   
Using animal models of ICH and excitotoxicity-induced chronic neurodegeneration, 
we show that reactive astrocytes increased their expression of ZIP14 as a response to 
iron accumulation and inflammation. Reactive astrocytes exert neuroprotective as 
well as deleterious effects. They are less susceptible to iron toxicity than neurons and 
thus upregulation of ZIP14 in reactive astrocytes in ICH and chronic 
neurodegeneration may serve a protective role for neurons by limiting available iron. 
However, research focusing on the communication between glial cells and neurons 
may further outline the role of ZIP14 in iron homeostasis in CNS health and disease. 
Unraveling the role of ZIP14 in brain pathology and understanding of whether 
upregulation may be neuroprotective or neurotoxic, can be key to target these diseases 
therapeutically. 
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